Analyzing Analyst Recommendations: Flotek Industries, Inc. (FTK), CymaBay Therapeutics, Inc. (CBAY)

Flotek Industries, Inc. (NYSE:FTK) tinted gains of +7.5% (+0.24 points) to US$3.44. The volume of 1.2 Million shares climbed down over an trading activity of 1.27 Million shares. EPS ratio determined by looking at last 12 month figures is -1.37. Over the same time span, the stock marked US$6.77 as its best level and the lowest price reached was US$0.95. The corporation has a market cap of US$195.53 Million.

Flotek Industries, Inc. (NYSE:FTK)’s earnings per share has been growing at a -16 percent rate over the past 5 year when average revenue increase was noted as 0.3 percent. The return on equity ratio or ROE stands at -38 percent while most common profitability ratio return on investment (ROI) was -1.5 percent. The company’s institutional ownership is monitored at 62.6 percent. The company’s net profit margin has achieved the current level of -33.2 percent and possesses 26.8 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) is worth US$750.26 Million and has recently risen 7.45% to US$12.69. The latest exchange of 1.07 Million shares is below its average trading activity of 641.26 Million shares. The day began at US$12.6 but the price moved to US$11.93 at one point during the trading and finally capitulating to a session high of US$13.2. The stock tapped a 52-week high of US$15.59 while the mean 12-month price target for the shares is US$21.5.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.99, and a price to sales ratio of 144.28. For the past 5 years, the company’s revenue has grown 26.8%, while the company’s earnings per share has grown 17.7%. With an institutional ownership near 97.6%, it carries an earnings per share ratio of -1.04.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 7 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.9.